As of 17th November 2022, 15 ongoing clinical trials are being conducted testing the efficacy and safety of SGLT2 inhibitors on heart failure, diabetes mellites type 2, acute myocardial infarction, and chronic kidney disease (Table 2). Here, SLC5A2 is linked to acute myocardial infarction.